Success seen in fighting CME bias

Progress in keeping commercial bias from industry-based certified CME is at hand, say those who produce and fund it.

“For the most part…grantor companies in CME are following the rules because they have gotten the message. Providers of CME are following the rules,” said John Kamp, executive director, Coalition for Healthcare Communication, in a new video, Conflict of Interest: The Bottom Line, produced by CME Peer Review, an independent review organization.

But keeping med ed independent remains a struggle—there is a 38% non-compliance rate for conflict of interest disclosures, per the Accreditation Council for CME (ACCME).
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.